454 related articles for article (PubMed ID: 10418180)
1. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
Hsu HC; Chen YF; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
[TBL] [Abstract][Full Text] [Related]
2. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
Schwartz RS; Abildgaard CF; Aledort LM; Arkin S; Bloom AL; Brackmann HH; Brettler DB; Fukui H; Hilgartner MW; Inwood MJ
N Engl J Med; 1990 Dec; 323(26):1800-5. PubMed ID: 2123300
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
Arkin S; Rose E; Forster A; Aledort LM
Semin Hematol; 1991 Apr; 28(2 Suppl 1):47-51. PubMed ID: 1908129
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.
Hyun SY; Park SY; Lee SY; Kook H; Paik SH; Jang IJ; Lee KS
Yonsei Med J; 2015 Jul; 56(4):935-43. PubMed ID: 26069114
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor VIII in hemophilia A: the Canadian experience.
Blanchette VS
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
[TBL] [Abstract][Full Text] [Related]
8. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
[TBL] [Abstract][Full Text] [Related]
9. [Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies].
Perret BA; Poorbeik M; Morell A
Schweiz Med Wochenschr; 1991 Nov; 121(44):1624-7. PubMed ID: 1947960
[TBL] [Abstract][Full Text] [Related]
10. [Current status and future prospects of hemophilia treatment].
Lopaciuk S
Acta Haematol Pol; 1995; 26(2 Suppl 1):44-55. PubMed ID: 7653234
[TBL] [Abstract][Full Text] [Related]
11. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
Abshire TC; Brackmann HH; Scharrer I; Hoots K; Gazengel C; Powell JS; Gorina E; Kellermann E; Vosburgh E
Thromb Haemost; 2000 Jun; 83(6):811-6. PubMed ID: 10896230
[TBL] [Abstract][Full Text] [Related]
12. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
Brinkhous KM
Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
14. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.
Seremetis S; Lusher JM; Abildgaard CF; Kasper CK; Allred R; Hurst D
Haemophilia; 1999 Jan; 5(1):9-16. PubMed ID: 10215942
[TBL] [Abstract][Full Text] [Related]
15. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia.
White GC; McMillan CW; Kingdon HS; Shoemaker CB
N Engl J Med; 1989 Jan; 320(3):166-70. PubMed ID: 2492083
[No Abstract] [Full Text] [Related]
16. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
Mannucci PM
Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
[TBL] [Abstract][Full Text] [Related]
17. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation.
Soucie JM; Siwak EB; Hooper WC; Evatt BL; Hollinger FB;
Transfusion; 2004 Aug; 44(8):1179-85. PubMed ID: 15265122
[TBL] [Abstract][Full Text] [Related]
18. [Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates].
Tavares A; Galvão M
Acta Med Port; 1992 Dec; 5(11):587-90. PubMed ID: 1293952
[TBL] [Abstract][Full Text] [Related]
19. The current status of recombinant human factor VIII.
Aronson DL
Semin Hematol; 1991 Apr; 28(2 Suppl 1):55-6. PubMed ID: 1908131
[No Abstract] [Full Text] [Related]
20. Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A.
Kelly KM; Butler RB; Farace L; Cohen AR; Manno CS
J Pediatr; 1997 Apr; 130(4):537-40. PubMed ID: 9108849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
